Pierre Armand Morgon

SVP of International Business Operation at Tianjin CanSino Biologics

Pierre Armand MORGON joined the company as Senior Vice President of International Business Operation in 2020. Pierre has over 30 years of experience in the global life science industry, especially with specialty care, vaccines and immunotherapy, at the helm of international operations, in C-level positions at global level in multinational corporations and as CEO of start-up companies. Currently, Pierre also serves as CEO of MRGN Advisors and Regional Partner for Switzerland at Mérieux Equity Partners. He is Chairman of the Boards of Theradiag and of Eurocine Vaccines, as well as Non-Executive Director to the Boards of Vaccitech and Univercells. Additionally, he is a lecturer in several MBA programs and in life science conferences, and at the Mass Challenge incubator in Switzerland where he is also a mentor for start-up life sciences companies. Pierre holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD and IMD.